Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1911 1
1924 1
1946 2
1948 1
1951 2
1952 1
1954 2
1956 1
1958 3
1959 1
1960 1
1963 1
1964 4
1965 3
1966 2
1967 7
1968 4
1969 3
1970 1
1971 5
1972 6
1973 6
1974 1
1975 7
1976 4
1977 6
1978 5
1979 12
1980 4
1981 4
1982 13
1983 4
1984 2
1985 8
1986 9
1987 5
1988 6
1989 14
1990 8
1991 7
1993 12
1994 5
1995 5
1996 11
1997 5
1998 7
1999 10
2000 9
2001 14
2002 13
2003 15
2004 14
2005 11
2006 13
2007 26
2008 24
2009 21
2010 19
2011 16
2012 24
2013 18
2014 17
2015 17
2016 15
2017 21
2018 18
2019 6
2020 16
2021 16
2022 12
2023 24
2024 31
2025 25

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

644 results

Results by year

Filters applied: . Clear all
Page 1
Propagative α-synuclein seeds as serum biomarkers for synucleinopathies.
Okuzumi A, Hatano T, Matsumoto G, Nojiri S, Ueno SI, Imamichi-Tatano Y, Kimura H, Kakuta S, Kondo A, Fukuhara T, Li Y, Funayama M, Saiki S, Taniguchi D, Tsunemi T, McIntyre D, Gérardy JJ, Mittelbronn M, Kruger R, Uchiyama Y, Nukina N, Hattori N. Okuzumi A, et al. Among authors: mcintyre d. Nat Med. 2023 Jun;29(6):1448-1455. doi: 10.1038/s41591-023-02358-9. Epub 2023 May 29. Nat Med. 2023. PMID: 37248302 Free PMC article.
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.
Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson DA. Olive KP, et al. Among authors: mcintyre d. Science. 2009 Jun 12;324(5933):1457-61. doi: 10.1126/science.1171362. Epub 2009 May 21. Science. 2009. PMID: 19460966 Free PMC article.
Letter from Luxembourg.
Beyenburg S, McIntyre D. Beyenburg S, et al. Among authors: mcintyre d. Pract Neurol. 2012 Feb;12(1):60-2. doi: 10.1136/practneurol-2011-000148. Pract Neurol. 2012. PMID: 22258175 No abstract available.
Whither health economics?
Mooney G, McIntyre D. Mooney G, et al. Among authors: mcintyre d. Aust N Z J Public Health. 2009 Aug;33(4):305-6. doi: 10.1111/j.1753-6405.2009.00399.x. Aust N Z J Public Health. 2009. PMID: 19689588 Free article. No abstract available.
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab.
Ricciuti B, Elkrief A, Lin J, Zhang J, Alessi JV, Lamberti G, Gandhi M, Di Federico A, Pecci F, Wang X, Makarem M, Hidalgo Filho CM, Gorria T, Saini A, Pabon C, Lindsay J, Pfaff KL, Welsh EL, Nishino M, Sholl LM, Rodig S, Kilickap S, Rietschel P, McIntyre DA, Pouliot JF, Altan M, Gainor JF, Heymach JV, Schoenfeld AJ, Awad MM. Ricciuti B, et al. Among authors: mcintyre da. JTO Clin Res Rep. 2024 Apr 12;5(9):100675. doi: 10.1016/j.jtocrr.2024.100675. eCollection 2024 Sep. JTO Clin Res Rep. 2024. PMID: 39399157 Free PMC article.
Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non-small cell lung cancer with programmed cell death-ligand 1 ≥50.
Kilickap S, Özgüroğlu M, Sezer A, Gümüş M, Bondarenko I, Gogishvili M, Turk HM, Cicin I, Bentsion D, Gladkov O, Sriuranpong V, Quek RGW, McIntyre DAG, He X, McGinniss J, Seebach F, Gullo G, Rietschel P, Pouliot JF. Kilickap S, et al. Among authors: mcintyre dag. Cancer. 2025 May 15;131(10):e35864. doi: 10.1002/cncr.35864. Cancer. 2025. PMID: 40323717 Free PMC article. Clinical Trial.
Machine learning for microfluidic design and control.
McIntyre D, Lashkaripour A, Fordyce P, Densmore D. McIntyre D, et al. Lab Chip. 2022 Aug 9;22(16):2925-2937. doi: 10.1039/d2lc00254j. Lab Chip. 2022. PMID: 35904162 Free PMC article. Review.
Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study.
Smithy JW, Kalvin HL, Ehrich FD, Shah R, Adamow M, Raber V, Maher CA, Kleman J, McIntyre DAG, Shoushtari AN, Betof Warner A, Callahan MK, Momtaz P, Eton O, Nair S, Wolchok JD, Chapman PB, Berger MF, Panageas KS, Postow MA. Smithy JW, et al. Among authors: mcintyre dag. Clin Cancer Res. 2024 Aug 15;30(16):3407-3415. doi: 10.1158/1078-0432.CCR-23-3643. Clin Cancer Res. 2024. PMID: 38767650 Free PMC article. Clinical Trial.
644 results